<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308070">
  <stage>Registered</stage>
  <submitdate>16/06/2009</submitdate>
  <approvaldate>19/06/2009</approvaldate>
  <actrnumber>ACTRN12609000492257</actrnumber>
  <trial_identification>
    <studytitle>Weight loss and type 2 diabetes study 2009</studytitle>
    <scientifictitle>A 12 month parallel study comparing generic weight loss advice versus meal replacement on weight loss in overweight people with type 2 diabetes</scientifictitle>
    <utrn />
    <trialacronym>MR</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity and diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Overweight  subjects with type 2 diabetes will be randomized to either a generic weight loss advice group or they will be randomized to a  meal replacement group.The weight loss advice group will be attending a group information session at the start of the study. That group will be asked to follow that advice for 12 months.The meal replacement group will consume 2 meal replacements/day until a weight loss of 10% is achieved and will then switch to one meal replacement/day, for a total trial duration of 12 months.The product will be manufactured by Probiotec..</interventions>
    <comparator>Overweight subjects with type 2 diabetes will be given an information book on diet and lifestyle and asked to follow dietary advice provided within this book for the duration of the study which is 12 months.  No professional advice will be provided other than one hours introductory group session at the start of the study.</comparator>
    <control>Active</control>
    <interventioncode>Lifestyle</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcomes are weight, body composition (fat distribution) measured by dual energy X-ray absorptiometry and Glycosylated haemoglobin (HbA1c).</outcome>
      <timepoint>Baseline at 3 months and at 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically monitor fasting lipids and glucose, by blood analysis and blood pressure measurements.</outcome>
      <timepoint>Baseline at 3 months and at 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Body Mass Index greater than27.
Weight limit of 130kg. 
Type 2 diabetes diet controlled, on oral hypoglycaemic medication or on insulin.
 HbA1c less than 9%</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known lactose intolerance or dairy allergy .
Participation in a study within 30 days of commencement of the study.
Weight changes of more than 3kg over last 3 months.
Taking any medications which may interfere with study parameters.
Untreated hypertension 
Systolic Blood Pressure more than 150 mmHg.
Person considered by the investigator to be unwilling, unlikely or unable to comprehend or comply with the study protocol and restrictions.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>27/07/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Probiotec Limited</primarysponsorname>
    <primarysponsoraddress>83 Cherry Lane
Laverton North
VICTORIA
3026</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Probiotec Limited</fundingname>
      <fundingaddress>83 Cherry Lane
Laverton North
VICTORIA
3026</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Peter Clifton</name>
      <address>CSIRO Human Nutrition
Gate 13
Kintore Ave
Adelaide SA 5000</address>
      <phone>+61 83038826</phone>
      <fax>+61 83038899</fax>
      <email>peter.clifton@csiro.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Julia Weaver</name>
      <address>CSIRO Human Nutrition
Gate 13
Kintore Ave
Adelaide SA 5000</address>
      <phone>+61 83038876</phone>
      <fax>+61 83038899</fax>
      <email>julia.weaver@csiro.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Julia Weaver</name>
      <address>CSIRO Human Nutrition
Gate 13
Kintore Ave
Adelaide SA 5000</address>
      <phone>+61 83038876</phone>
      <fax>+61 83038899</fax>
      <email>julia.weaver@csiro.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>